Pelthos Therapeutics Inc. Costs and Expenses
Pelthos Therapeutics Inc. (PTHS) reported Costs and Expenses of $32.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-13
- Pelthos Therapeutics Inc. costs and expenses for the quarter ending 2026-06-30 was $32.93M, a 919.07% increase year-over-year.
- Pelthos Therapeutics Inc. costs and expenses for the quarter ending 2026-03-31 was $23.99M, a 1208.29% increase year-over-year.
- Pelthos Therapeutics Inc. costs and expenses for the quarter ending 2025-06-30 was $3.23M.
- Pelthos Therapeutics Inc. costs and expenses for the quarter ending 2025-03-31 was $1.83M.
- Pelthos Therapeutics Inc. costs and expenses for fiscal 2025 was $49.23M, a 550.18% increase from fiscal 2024.
- Pelthos Therapeutics Inc. costs and expenses for fiscal 2024 was $7.57M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 12 month |
|---|---|---|---|
| 2026-06-30 | $32.93M 10-Q · filed 2026-08-13 | $56.92M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $23.99M 10-Q/A · filed 2026-08-13 | ||
| 2025-12-31 | $49.23M 10-K · filed 2026-03-19 | ||
| 2025-06-30 | $3.23M 10-Q · filed 2026-08-13 | $5.07M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $1.83M 10-Q/A · filed 2026-08-13 | ||
| 2024-12-31 | $7.57M 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |